（原标题：众生药业龙虎榜数据（7月29日）） 众生药业今日涨停，全天换手率15.34%，成交额22.60亿元，振幅10.78%。龙虎榜数据显示，机构净买 入8309.12万元，深股通净买入6267.61万元，营业部席位合计净买入3514.45万元。 资金流向方面，今日该股主力资金净流入3.03亿元，其中，特大单净流入2.64亿元，大单资金净流入 3821.06万元。近5日主力资金净流入3.48亿元。 融资融券数据显示，该股最新（7月28日）两融余额为6.37亿元，其中，融资余额为6.34亿元，融券余额 为303.01万元。近5日融资余额合计减少184.10万元，降幅为0.29%，融券余额合计增加17.52万元，增幅 6.14%。（数据宝） | 买/卖 | 会员营业部名称 | 买入金额（万元） | 卖出金额（万元） | | --- | --- | --- | --- | | 买一 | 深股通专用 | 18509.35 | 12241.74 | | 买二 | 机构专用 | 7271.60 | 1783.10 | | 买三 | 国泰海通证券股份有限公司宜昌沿江大道证券营业部 | 6186.13 | 20.47 | ...

医药生物行业今日上涨2.06%，全天主力资金净流入29.96亿元，该行业所属的个股共474只，今日上涨 的有341只，涨停的有11只；下跌的有128只，跌停的有1只。以资金流向数据进行统计，该行业资金净 流入的个股有258只，其中，净流入资金超亿元的有10只，净流入资金居首的是众生药业，今日净流入 资金3.03亿元，紧随其后的是智飞生物、九洲药业，净流入资金分别为2.56亿元、2.50亿元。医药生物 行业资金净流出个股中，资金净流出超亿元的有7只，净流出资金居前的有恒瑞医药、塞力医疗、药明 康德，净流出资金分别为3.52亿元、1.87亿元、1.73亿元。（数据宝） 医药生物行业资金流入榜 | 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量（万元） | | --- | --- | --- | --- | --- | | 002317 | 众生药业 | 9.98 | 15.34 | 30259.16 | | 300122 | 智飞生物 | 6.50 | 9.19 | 25584.13 | | 603456 | 九洲药业 | 10.01 | 12.54 | 24987.61 | | 3 ...

今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | CRO概念 | 4.00 | 猪肉 | -1.35 | | 重组蛋白 | 2.90 | 养鸡 | -1.12 | | 创新药 | 2.79 | 草甘膦 | -1.10 | | 减肥药 | 2.76 | 粮食概念 | -1.00 | | F5G概念 | 2.43 | 芬太尼 | -0.88 | | 细胞免疫治疗 | 2.42 | PEEK材料 | -0.85 | | 仿制药一致性评价 | 2.30 | 预制菜 | -0.85 | | 共封装光学(CPO) | 2.23 | 生态农业 | -0.78 | | 特钢概念 | 2.08 | C2M概念 | -0.78 | | 先进封装 | 1.91 | 人造肉 | -0.76 | 截至7月29日收盘，仿制药一致性评价概念上涨2.30%，位居概念板块涨幅第7，板块内，104股上涨， 亚太药业、九洲药业、辰欣药业等涨停，南新制药、苑东生物、海特生物等涨幅居前，分别上涨 17.01%、15.45%、15.28%。跌幅居前的有昂 ...

减肥药概念资金流入榜 | 代码 | 简称 | 今日涨跌幅 | 今日换手率 | 主力资金流量（万 | 主力资金净流入比率 | | --- | --- | --- | --- | --- | --- | | | | （%） | （%） | 元） | （%） | | 002317 | 众生药 业 | 9.98 | 15.34 | 30259.16 | 13.39 | | 300122 | 智飞生 物 | 6.50 | 9.19 | 25584.13 | 8.11 | | 300765 | 新诺威 | 7.10 | 1.03 | 9329.48 | 13.00 | | 002294 | 信立泰 | 3.68 | 1.39 | 9194.53 | 11.73 | | 002038 | 双鹭药 业 | 7.09 | 9.67 | 7891.35 | 11.45 | | 002821 | 凯莱英 | 4.13 | 4.86 | 7719.47 | 4.12 | | 300199 | 翰宇药 业 | 4.97 | 21.02 | 7338.57 | 2.48 | | 000513 | 丽珠集 | 0.07 | 3.00 | ...

截至7月29日收盘，创新药概念上涨2.79%，位居概念板块涨幅第3，板块内，195股上涨，睿智医药20% 涨停，奥翔药业、亚太药业、九洲药业等涨停，三元基因、药石科技、南新制药等涨幅居前，分别上涨 20.76%、18.77%、17.01%。跌幅居前的有昂利康、*ST苏吴、多瑞医药等，分别下跌6.16%、5.04%、 4.66%。 今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | CRO概念 | 4.00 | 猪肉 | -1.35 | | 重组蛋白 | 2.90 | 养鸡 | -1.12 | | 创新药 | 2.79 | 草甘膦 | -1.10 | | 减肥药 | 2.76 | 粮食概念 | -1.00 | | F5G概念 | 2.43 | 芬太尼 | -0.88 | | 细胞免疫治疗 | 2.42 | PEEK材料 | -0.85 | | 仿制药一致性评价 | 2.30 | 预制菜 | -0.85 | | 共封装光学(CPO) | 2.23 | 生态农业 | -0.78 | | 特钢概念 | 2.08 | C2 ...

证券之星消息，7月29日中药板块较上一交易日上涨1.0%，佛慈制药领涨。当日上证指数报收于 3609.71，上涨0.33%。深证成指报收于11289.41，上涨0.64%。中药板块个股涨跌见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入(元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 002317 众生药业 | | 3.08亿 | 13.62% | -2.09亿 | -9.25% | -9887.67万 | -4.37% | | 300158 振东制药 | | 9631.85万 | 6.34% | -3070.18万 | -2.02% | -6561.68万 | -4.32% | | 686000 | 九芝堂 | 7562.48万 | 11.69% | 2336.98万 | 3.61% | -9899.45万 | -15.30% | | 002907 | 华森制药 | 6726.09万 | 9.79% | -650.70万 | -0.95% | -6075 ...

Market Overview - The Shanghai Composite Index rose by 0.12% on July 28, with 15 sectors experiencing gains, led by defense and non-bank financials, which increased by 1.86% and 1.51% respectively. The pharmaceutical and biological sector ranked third in terms of gains [1] - Conversely, the coal and steel sectors saw declines of 2.60% and 1.41% respectively [1] Fund Flow Analysis - The main funds in the two markets experienced a net outflow of 18.575 billion yuan, with 8 sectors seeing net inflows. The electronics sector led with a net inflow of 3.655 billion yuan and a daily increase of 1.10%, followed by the communications sector with a net inflow of 2.848 billion yuan and a daily increase of 1.24% [1] - In contrast, 23 sectors faced net outflows, with the computer sector leading at a net outflow of 6.892 billion yuan, followed by the non-ferrous metals sector with a net outflow of 3.254 billion yuan [1] Pharmaceutical and Biological Sector Performance - The pharmaceutical and biological sector increased by 1.47% with a net inflow of 314 million yuan. Out of 474 stocks in this sector, 265 rose, 9 hit the daily limit up, while 191 fell, with 2 hitting the daily limit down [2] - Notably, 178 stocks in this sector experienced net inflows, with 8 stocks seeing inflows exceeding 100 million yuan. The top stock for net inflow was Heng Rui Medicine, with an inflow of 1.256 billion yuan, followed by Lu Kang Medicine and Zhong Sheng Pharmaceutical with inflows of 181 million yuan and 169 million yuan respectively [2] Top Gainers in Pharmaceutical Sector - The top gainers in the pharmaceutical sector included: - Heng Rui Medicine: +10.00% with a turnover rate of 2.56% and a main fund flow of 1.255 billion yuan - Lu Kang Medicine: +4.30% with a turnover rate of 15.05% and a main fund flow of 181 million yuan - Zhong Sheng Pharmaceutical: +7.88% with a turnover rate of 11.59% and a main fund flow of 169 million yuan [3] Top Losers in Pharmaceutical Sector - The top losers in the pharmaceutical sector included: - Changshan Pharmaceutical: -0.28% with a main fund outflow of 122.818 million yuan - Shenzhou Cell: -1.14% with a main fund outflow of 102.235 million yuan - WuXi AppTec: +3.08% with a main fund outflow of 94.187 million yuan [4]

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry [1] Core Views - The innovation environment is continuously improving, leading to an optimistic outlook on innovation premiums. In the first half of 2025, global pharmaceutical transactions reached 456, a 32% year-on-year increase, with total upfront payments soaring to $11.8 billion, a 136% increase. The total transaction value hit $130.4 billion, up 58% year-on-year, with Chinese companies contributing nearly 50% of the total value and over 30% of the transaction count [3] - The CXO sector is expected to gradually recover following a supply-side cleansing post-COVID-19, with a significant increase in License-out transactions and total transaction amounts surpassing previous years [4] - The TCE technology is being continuously iterated and updated, with promising clinical data emerging for TCE-based therapies, indicating a strong market potential [5] - The trend towards more effective and scientific weight loss solutions is evident, with GLP-1 drugs generating over $50 billion in global sales, driving capital interest in the sector [6] - There is a growing focus on autoimmune diseases, with significant clinical data supporting new treatments and collaborations in the field [7] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry outperformed the CSI 300 index by 0.21 percentage points in the last week, with a weekly increase of 1.90% [18] - Over the past month, the industry outperformed the CSI 300 index by 6.73 percentage points, with a monthly increase of 10.95% [21][24] 2. Pharmaceutical Sector Trends and Valuation - The pharmaceutical and biotechnology industry index currently has a PE (TTM) of 37.98, above the 5-year historical average of 32.08 [41] 3. Recent Research Achievements - The report highlights various recent research findings, including the positive outlook for the blood products industry and the acceleration of the inhalation drug sector due to policy support [45] 4. Recent Industry Policies and News - The National Healthcare Security Administration has implemented measures to support the high-quality development of innovative drugs, enhancing the support for R&D and clinical applications [46] - Recent news includes significant approvals and collaborations in the pharmaceutical sector, indicating a vibrant market environment [48][49] 5. Key Company Recommendations - The report recommends specific companies based on their potential to benefit from the improving innovation environment and market trends, including CXO firms and those involved in TCE technology [8]

证券代码：002317 公告编号：2025-077 广东众生药业股份有限公司 关于全资子公司获得氯贝酸铝化学原料药 上市申请批准通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广东众生药业股份有限公司（以下简称"公司"）全资子公司广东先强药业 有限公司于近日收到国家药品监督管理局核准签发的原料药氯贝酸铝《化学原料 药上市申请批准通知书》。现就相关情况公告如下： 一、《化学原料药上市申请批准通知书》的主要内容 登记号：Y20230001298 通知书编号：2025YS00606 化学原料药名称：氯贝酸铝 申请事项：境内生产化学原料药上市申请 生产企业：名称：广东先强药业有限公司，地址：广州市从化经济开发区工 业大道 6 号 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册。 二、药品简介 氯贝酸铝是氯贝丁酸衍生物类血脂调节药，在胃中不分解，对胃无刺激，在 肠道碱性环境中分解为氯贝丁酯而起作用。氯贝酸铝通过降低极低密度脂蛋白的 量，达到降血脂的目的。氯贝酸铝作为有效成分应用于脂降宁片（安络宁片）、 ...

Core Viewpoint - The pharmaceutical industry is undergoing a profound transformation from "following innovation" to "source breakthrough," driven by new quality productivity and technological innovation [2][12]. Company Overview - Guangdong Zhongsheng Pharmaceutical Co., Ltd. was established in 1979 and listed on the Shenzhen Stock Exchange in December 2009, with stock code 002317 [4]. - The company integrates drug research and development, production, and sales, positioning itself as one of China's top 100 pharmaceutical companies [4]. - Zhongsheng Pharmaceutical focuses on high-quality products and services, with a product portfolio covering major disease areas such as cardiovascular, respiratory, ophthalmology, and digestion [4]. Innovation and Product Development - The company has established a development strategy centered on traditional Chinese medicine, innovation, and focusing on specialty areas, with core products including the Compound Thrombus Tong series and Brain Thrombus Tong capsules [4]. - Zhongsheng is the only domestic company with innovative drugs for both COVID-19 and influenza, having successfully launched the first peptide 3CL single-agent antiviral drug for COVID-19 and the first RNA polymerase PB2 protein inhibitor for influenza [4][8]. - The company has invested in innovative drug development, with two new drugs launched recently, including the innovative drug for treating adult influenza, which was approved in May [8]. Digital Transformation - The company is investing 300 million yuan in its subsidiary to create a smart, digital, and intensive traditional Chinese medicine extraction workshop [9]. - Advanced technologies such as cloud computing, big data, artificial intelligence, and IoT are being utilized to enhance the entire pharmaceutical supply chain [7][9]. Sustainable Development Strategy - Zhongsheng emphasizes the coordination between traditional and emerging businesses, proposing a sustainable development structure that includes innovative drugs as the leading force, traditional Chinese medicine as the foundation, and chemical generics as support [10]. - The company has maintained a research and development investment of over 8% of its revenue annually since 2010, with recent years exceeding 10% [12]. Industry Trends - The core of new quality productivity in the biopharmaceutical industry lies in technological innovation and the transformation of results [6]. - The industry is expected to evolve towards innovation-driven and high-quality growth, supported by policy, market changes, and technological advancements [6].